Drug Discovery and Early Development Outsourcing Services Industry Analysis – M&As, Partnerships and the Shift Toward an End-to-end CRDMO Model will Boost Sector Expansion – ResearchAndMarkets.com
Digital Health Global
APRIL 5, 2024
growth between 2023 to 2024. Furthermore, the industry witnessed a decline in the average return on investment (ROI) for R&D to as low as 1.2%, and the peak sales per asset valued just above $350 million, indicating a need to build more efficient drug development processes with the implementation of newer technologies.
88 
Let's personalize your content